- Androgenetic alopecia affects up to 70% of men and 40% of women, causing billions to be spent annually on ineffective treatments. A novel topical formulation is proposed that safely and painlessly increases hair growth as an alternative to hair transplants or minoxidil, which often does not work. Animal testing has been completed and clinical trials in humans are needed, requiring funding and research partners. The technology is patented and seeking licensing for further development and testing.

1. Treatment for Alopecia
May 30, 2019

2. What is the problem?
– Androgenetic alopecia (hair loss), affecting up to 70% of
men and 40% of women.
– American hair loss sufferers spend more than 3.5 billion
dollars a year in an attempt to treat their hair loss.
– An estimated 310,624 surgical hair restoration
procedures were performed worldwide in 2012 (a 10%
increase from 2010).
– US had the most at 88,304 hair restoration procedures
performed
– Worldwide market for hair restoration is 2 billion dollars.
Presenter: Aswini K. Betha, PhD

3. How does product/service solve problem?
–Novel formulation that increases hair
growth.
–To treat pattern baldness in men and
women
–To treat hair loss induced by
chemotherapy in cancer survivors.
–Safe and painless topical formulation.
Presenter: Aswini K. Betha, PhD

4. What is the market use?
Presenter: Aswini K. Betha, PhD
• Safe, painless, effective and easy to
apply scalp application (non-invasive).
• Safe and painless topical formulation.
• Alternative for hair transplantation.
• No adverse effects at high doses.
• Can replace the currently ineffective
and painful treatments.

5. What competition exists?
• May work better than Minoxidil.
–Minoxidil does not work for most patients:
• 15% will experience some sort of hair
regrowth.
• 50% have their hair loss delayed.
• 35% will continue to lose hair.
Presenter: Aswini K. Betha, PhD

6. What is the status of the intellectual property?
• Patents issued in US:
– US Issued Patent # 7,825,217
– US Issued Patent # 10,213,479
• Additional patents pending
Presenter: Aswini K. Betha, PhD

7. What is the stage of development?
• Animal Experiments done.
Presenter: Aswini K. Betha, PhD

8. What is needed for further development?
• Determine long-term stability of the
formulation.
• Comprehensive testing of diverse gel
formulations.
• Testing in humans (clinical trials).
• Looking for funding and research partners.
• Technology available for licensing.
Presenter: Aswini K. Betha, PhD